AMVUTTRA™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Administration and Dosage:
AMVUTTRA™ is dosed 4 times per year via subcutaneous injection
Common Side Effects:
The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).
More Information:
Please see full Prescribing Information including Patient Information.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
Indication:
AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
